A Phase 3 interventional study of Abrocitinib 200 mg and Dupilumab 300 mg in Atopic Dermatitis, sponsored by Pfizer. Completed at 151 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-08.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 10 in phase 3, and was the 11th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer
Ages 2–5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 727 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 150 across the 20 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
58 studies in Dermatitis, Atopic by Pfizer: 11 open now, 13 under way, 4 of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 7th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2020, is one of 17 in phase 3, and was the 29th registered.
Pfizer’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing abrocitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07848074Fondazione Policlinico Universitario Agostino Gemelli IRCCSAbrocitinib Dose Tapering in Patients With Atopic Dermatitis | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, from their registry updates:
Among Pfizer’s 58 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg administered by subcutaneous injection every other week (as per label guidelines) in adult participants on background topical therapy, with moderate to severe AD. The treatment duration is 26 weeks. A total of approximately 600 participants will be enrolled from approximately 220 sites globally. Approximately 600 participants will be randomly assigned to study intervention. There are primary efficacy assessments at Week 2 and Week 4, and a key secondary efficacy assessment at Week 16. Efficacy and safety endpoints will be assessed throughout the entire study. Exploratory endpoints related to hand eczema efficacy will be assessed throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
Drug: Abrocitinib 200 mg
Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
Combination Product: Dupilumab 300 mg
Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2
The severity of itch (pruritus) due to atopic dermatitis (AD) was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
Time frame: Week 2
Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4
EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
Time frame: Week 4
Percentage of Participants Achieving EASI-90 Response at Week 16
EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
Time frame: Week 16
Percentage of Participants Achieving EASI-90 Response at Weeks 2, 8, 12, 20 and 26
EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
Time frame: Week 2, 8, 12, 20 and 26
Percentage of Participants Achieving >= 75% Improvement From Baseline in EASI (EASI-75) Response at Weeks 2, 4, 8, 12, 16, 20 and 26
EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
Time frame: Week 2, 4, 8, 12, 16, 20 and 26
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline up to Week 26
IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, except any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation); 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting.
Time frame: Week 2, 4, 8, 12, 16, 20 and 26
Percentage of Participants Achieving PP-NRS4 From Baseline at Days 2 to 15
The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
Time frame: Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Percentage of Participants Achieving PP-NRS4 From Baseline at Week 4, 8, 12, 16, 20 and 26
The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
Time frame: Week 4, 8, 12, 16, 20 and 26
Time to Achieve >=4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4)
The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
Time frame: Baseline (Day 1) up to Week 30
Percent Change From Baseline in the Percentage (%) Body Surface Area (BSA) Affected at Week 2, 4, 8, 12, 16, 20 and 26
The extent (%) to which a body region was involved with AD was determined using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Total number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual was derived as sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater severity of AD.
Time frame: Baseline (Day 1), Week 2, 4, 8, 12, 16, 20 and 26
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8, 12, 16, 20 and 26
SCORAD is a scoring index for AD which combined extent (A), severity (B) and subjective symptoms (C). For A, a rule of 9 was used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region was added to determine A (range: 0-100). B: severity of each sign (erythema; edema/papulation; oozing/crusting; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores were added to give B (range: 0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using visual analog scale (VAS) where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss were added to give 'C' (range: 0-20). SCORAD total score was calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Baseline (Day 1), Week 2, 4, 8, 12, 16, 20 and 26
Change From Baseline in Total Anxiety Score Measured Using the Hospital Anxiety and Depression Scale (HADS) at Week 12,16 and 26
HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety.
Time frame: Baseline (Day 1), Week 12, 16 and 26
Change From Baseline in Total Depression Score Measured Using the HADS at Week 12,16 and 26
HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-D assessed the state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.
Time frame: Baseline (Day 1), Week 12, 16 and 26
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 2, 12, 16, 20 and 26
DLQI is a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score, ranging from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
Time frame: Baseline (Day 1), Week 2, 12, 16, 20 and 26
Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12, 16 and 26
The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a VAS that measured health state. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state.
Time frame: Baseline (Day 1), Week 12, 16 and 26
Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Week 12, 16 and 26
POEM was a 7-item participant reported outcome measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item was scored as: no days=0, 1-2 days=1, 3-4 days=2, 5-6 days=3 and every day=4. The item scores were added to provide a total score ranging from 0 to 28, where higher score indicated greater severity.
Time frame: Baseline (Day 1), Week 12, 16 and 26
Change From Baseline in Medical Outcomes Study - Sleep Scale (MOS-Sleep Scale) at Week 12, 16 and 26
The MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II). An additional single item assessed quantity of sleep. Each of the sleep domains were scored on a range of 0 to 100, and higher scores indicated worse outcomes. The quantity of sleep scores ranged from 0 to 24 (number of hours slept). Change from baseline scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.
Time frame: Baseline (Day 1), Week 12, 16 and 26
Change From Baseline in Skin Pain NRS at Week 2, 12, 16, 20 and 26
The skin pain NRS was a participant reported outcome where participants were asked to rate the "worst skin pain" in the past 24 hours on a 11-point scale from 0=no skin pain to 10=worst skin pain imaginable. Higher scores indicated worse pain.
Time frame: Baseline (Day 1), Week 2, 12, 16, 20 and 26
Medicated Topical Background Therapy-free Days
Medicated topical background therapy-free days was defined as number of days where a participant maintained a response of EASI-90 or greater without the use of medicated topical background therapy.
Time frame: Day 1 up to Week 26
Percentage of Participants Achieving >=4 Points Improvement From Baseline in DLQI at Week 2, 12, 16, 20 and 26
DLQI was a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
Time frame: Week 2, 12, 16, 20 and 26
Number of Participants With Treatment Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a treatment-emergent adverse event (TEAE) if the event started on or after the first dosing day until 28 days post last dose of study drug. AEs included both serious and non-serious AEs.
Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Number of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Discontinuation
An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; a congenital anomaly/birth defect and other important medical events.
Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Number of Participants With Laboratory Abnormalities Meeting Pre-Defined Criteria
The pre-defined criteria for laboratory parameters included: hemoglobin (\<9 grams per deciliter or decreases to \>=2 below baseline); platelets (\<75\*10\^3 cells per millimeter cube \[mm\^3\]); lymphocytes (\<0.5\*10\^3 cells per mm\^3); neutrophils (\<1\*10\^3 cells per mm\^3); aspartate aminotransferase and alanine aminotransferase (\>3\* upper limit of normal).
Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs including temperature, systolic and diastolic blood pressure, and pulse rate were measured in a seated position after 5 minutes rest. Clinically significant change from baseline in vital signs were determined by the investigator.
Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Data
A single 12-lead ECG was performed after the participant has rested for at least 10 minutes quietly in the supine position. Clinically significant change from baseline in ECG data was determined by the investigator.
Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
This was a double-blind, double-dummy, active-controlled study in adult participants with moderate to severe atopic dermatitis. The study was conducted across 143 sites in 15 countries.
| Milestone | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Started | 362 | 365 |
| Completed | 327 | 334 |
| Not completed | 35 | 31 |
| Withdrew: Other | 3 | 4 |
| Withdrew: Medication error without associated adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 11 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Adverse event | 10 | 9 |
The severity of itch (pruritus) due to atopic dermatitis (AD) was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 | 48.2 (43.0 to 53.4) | 25.5 (21.1 to 30.0) |
EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4 | 28.5 (23.8 to 33.2) | 14.6 (10.9 to 18.2) |
EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving EASI-90 Response at Week 16 | 54.3 (49.2 to 59.5) | 41.9 (36.8 to 47.0) |
EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | 11.6 (8.3 to 14.9) | 7.2 (4.5 to 9.8) |
| Week 8 | 45.4 (40.2 to 50.5) | 25.4 (20.9 to 29.9) |
| Week 12 | 47.6 (42.5 to 52.8) | 33.6 (28.7 to 38.5) |
| Week 20 | 58.4 (53.3 to 63.5) | 45.7 (40.6 to 50.9) |
| Week 26 | 54.6 (49.4 to 59.8) | 47.6 (42.5 to 52.8) |
EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | 29.4 (24.7 to 34.1) | 21.3 (17.1 to 25.5) |
| Week 4 | 57.6 (52.5 to 62.8) | 36.8 (31.9 to 41.8) |
| Week 8 | 71.0 (66.3 to 75.7) | 52.8 (47.6 to 57.9) |
| Week 12 | 76.3 (71.9 to 80.7) | 61.4 (56.4 to 66.4) |
| Week 16 | 77.3 (73.0 to 81.7) | 67.8 (63.0 to 72.6) |
| Week 20 | 76.1 (71.7 to 80.6) | 71.1 (66.4 to 75.7) |
| Week 26 | 73.0 (68.3 to 77.7) | 72.3 (67.7 to 76.9) |
IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, except any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation); 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | 14.4 (10.8 to 18.0) | 7.2 (4.5 to 9.8) |
| Week 4 | 38.0 (32.9 to 43.0) | 17.6 (13.7 to 21.5) |
| Week 8 | 50.1 (44.9 to 55.3) | 30.9 (26.2 to 35.7) |
| Week 12 | 51.8 (46.6 to 57.0) | 36.0 (31.1 to 40.9) |
| Week 16 | 55.3 (50.2 to 60.5) | 42.5 (37.4 to 47.6) |
| Week 20 | 60.0 (54.9 to 65.1) | 50.8 (45.7 to 56.0) |
| Week 26 | 55.6 (50.4 to 60.8) | 51.1 (46.0 to 56.3) |
The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Day 2 | 11.0 (7.5 to 14.4) | 3.8 (1.7 to 5.9) |
| Day 3 | 15.1 (11.3 to 18.8) | 8.6 (5.6 to 11.5) |
| Day 4 | 22.1 (17.7 to 26.4) | 10.7 (7.5 to 13.9) |
| Day 5 | 26.4 (21.8 to 31.0) | 11.9 (8.5 to 15.3) |
| Day 6 | 28.4 (23.7 to 33.2) | 15.5 (11.7 to 19.3) |
| Day 7 | 33.1 (28.2 to 38.1) | 13.2 (9.7 to 16.8) |
| Day 8 | 36.3 (31.2 to 41.3) | 14.1 (10.5 to 17.8) |
| Day 9 | 38.5 (33.4 to 43.6) | 16.9 (12.9 to 20.8) |
| Day 10 | 40.0 (34.8 to 45.2) | 18.7 (14.6 to 22.8) |
| Day 11 | 40.1 (35.0 to 45.3) | 20.2 (16.0 to 24.4) |
| Day 12 | 41.5 (36.3 to 46.7) | 20.2 (16.0 to 24.4) |
| Day 13 | 44.0 (38.8 to 49.2) | 21.5 (17.2 to 25.7) |
| Day 14 | 45.5 (40.3 to 50.8) | 23.2 (18.8 to 27.6) |
| Day 15 | 48.6 (43.3 to 53.8) | 25.6 (21.1 to 30.1) |
The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 4 | 58.1 (53.0 to 63.3) | 40.8 (35.7 to 45.8) |
| Week 8 | 65.8 (60.9 to 70.7) | 52.7 (47.6 to 57.9) |
| Week 12 | 66.0 (61.1 to 70.9) | 61.5 (56.5 to 66.5) |
| Week 16 | 67.2 (62.4 to 72.1) | 63.6 (58.7 to 68.6) |
| Week 20 | 65.3 (60.3 to 70.2) | 63.2 (58.2 to 68.1) |
| Week 26 | 68.1 (63.2 to 72.9) | 63.1 (58.1 to 68.0) |
The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.
| Days | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Time to Achieve >=4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) | 11.0 (9.0 to 14.0) | 25.0 (21.0 to 30.0) |
The extent (%) to which a body region was involved with AD was determined using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Total number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual was derived as sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater severity of AD.
| Percent change | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | -42.7 (-46.0 to -39.4) | -33.4 (-36.7 to -30.0) |
| Week 4 | -62.0 (-65.5 to -58.5) | -49.5 (-53.0 to -46.1) |
| Week 8 | -74.0 (-77.2 to -70.7) | -62.8 (-66.0 to -59.7) |
| Week 12 | -78.8 (-81.9 to -75.7) | -69.4 (-72.5 to -66.4) |
| Week 16 | -80.6 (-83.5 to -77.8) | -73.7 (-76.5 to -70.9) |
| Week 20 | -82.2 (-84.8 to -79.6) | -76.9 (-79.5 to -74.3) |
| Week 26 | -82.3 (-85.0 to -79.6) | -79.0 (-81.6 to -76.3) |
SCORAD is a scoring index for AD which combined extent (A), severity (B) and subjective symptoms (C). For A, a rule of 9 was used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region was added to determine A (range: 0-100). B: severity of each sign (erythema; edema/papulation; oozing/crusting; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores were added to give B (range: 0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using visual analog scale (VAS) where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss were added to give 'C' (range: 0-20). SCORAD total score was calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| Percent change | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | -44.5 (-47.0 to -42.1) | -33.5 (-35.9 to -31.0) |
| Week 4 | -59.6 (-61.9 to -57.3) | -46.8 (-49.1 to -44.5) |
| Week 8 | -65.8 (-68.2 to -63.4) | -55.6 (-58.0 to -53.3) |
| Week 12 | -67.9 (-70.2 to -65.6) | -60.6 (-62.9 to -58.3) |
| Week 16 | -70.6 (-72.8 to -68.3) | -64.4 (-66.7 to -62.2) |
| Week 20 | -71.8 (-74.1 to -69.4) | -66.8 (-69.1 to -64.5) |
| Week 26 | -71.5 (-73.9 to -69.1) | -68.2 (-70.6 to -65.9) |
HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 12 | -0.8 (-1.1 to -0.5) | -0.8 (-1.1 to -0.6) |
| Week 16 | -1.1 (-1.3 to -0.8) | -1.2 (-1.4 to -0.9) |
| Week 26 | -1.1 (-1.4 to -0.7) | -1.2 (-1.5 to -0.9) |
HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-D assessed the state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 12 | -0.7 (-1.0 to -0.5) | -0.7 (-1.0 to -0.5) |
| Week 16 | -0.8 (-1.0 to -0.5) | -0.9 (-1.1 to -0.7) |
| Week 26 | -0.8 (-1.0 to -0.5) | -1.0 (-1.3 to -0.8) |
DLQI is a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score, ranging from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | -8.6 (-9.1 to -8.2) | -6.7 (-7.1 to -6.2) |
| Week 12 | -10.7 (-11.1 to -10.2) | -9.7 (-10.1 to -9.3) |
| Week 16 | -10.8 (-11.2 to -10.4) | -10.0 (-10.5 to -9.6) |
| Week 20 | -10.8 (-11.2 to -10.3) | -10.1 (-10.6 to -9.7) |
| Week 26 | -10.3 (-10.8 to -9.9) | -10.0 (-10.5 to -9.6) |
The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a VAS that measured health state. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 12 | 12.370 (10.917 to 13.822) | 11.552 (10.123 to 12.981) |
| Week 16 | 12.567 (11.015 to 14.118) | 10.474 (8.951 to 11.997) |
| Week 26 | 13.484 (11.982 to 14.985) | 14.300 (12.836 to 15.764) |
POEM was a 7-item participant reported outcome measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item was scored as: no days=0, 1-2 days=1, 3-4 days=2, 5-6 days=3 and every day=4. The item scores were added to provide a total score ranging from 0 to 28, where higher score indicated greater severity.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 12 | -14.2 (-14.9 to -13.6) | -12.6 (-13.3 to -12.0) |
| Week 16 | -14.2 (-14.8 to -13.6) | -12.8 (-13.4 to -12.2) |
| Week 26 | -13.8 (-14.5 to -13.1) | -13.4 (-14.0 to -12.7) |
The MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II). An additional single item assessed quantity of sleep. Each of the sleep domains were scored on a range of 0 to 100, and higher scores indicated worse outcomes. The quantity of sleep scores ranged from 0 to 24 (number of hours slept). Change from baseline scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Quantity Hours Slept Score: Week 12 | 0.7 (0.5 to 0.9) | 0.5 (0.2 to 0.7) |
| Quantity Hours Slept Score: Week 16 | 0.6 (0.3 to 0.8) | 0.5 (0.3 to 0.7) |
| Quantity Hours Slept Score: Week 26 | 0.5 (0.3 to 0.7) | 0.4 (0.2 to 0.6) |
| Short of Breath or Headache score: Week 12 | -0.7 (-2.2 to 0.9) | -1.9 (-3.4 to -0.4) |
| Short of Breath or Headache score: Week 16 | -1.2 (-2.7 to 0.3) | -1.3 (-2.8 to 0.2) |
| Short of Breath or Headache score: Week 26 | -2.0 (-3.5 to -0.6) | -2.6 (-4.0 to -1.2) |
| Snoring Score: Week 12 | -5.3 (-7.0 to -3.6) | -3.5 (-5.2 to -1.8) |
| Snoring Score: Week 16 | -4.9 (-6.6 to -3.1) | -4.0 (-5.7 to -2.3) |
| Snoring Score: Week 26 | -3.9 (-5.7 to -2.0) | -4.7 (-6.5 to -2.9) |
| Sleep Disturbance Score: Week 12 | -20.5 (-22.3 to -18.8) | -16.4 (-18.1 to -14.7) |
| Sleep Disturbance Score: Week 16 | -21.5 (-23.2 to -19.7) | -17.7 (-19.4 to -16.0) |
| Sleep Disturbance Score: Week 26 | -21.2 (-23.0 to -19.5) | -19.5 (-21.2 to -17.8) |
| Sleep Adequacy Score: Week 12 | 13.9 (12.1 to 15.8) | 12.9 (11.1 to 14.7) |
| Sleep Adequacy Score: Week 16 | 15.7 (13.9 to 17.4) | 12.7 (11.0 to 14.5) |
| Sleep Adequacy Score: Week 26 | 14.0 (12.1 to 15.8) | 13.2 (11.4 to 15.1) |
| Sleep Somnolence Score: Week 12 | -7.7 (-9.1 to -6.2) | -6.9 (-8.3 to -5.5) |
| Sleep Somnolence Score: Week 16 | -9.8 (-11.3 to -8.4) | -7.4 (-8.8 to -6.0) |
| Sleep Somnolence Score: Week 26 | -9.9 (-11.3 to -8.5) | -7.6 (-9.0 to -6.2) |
| Sleep Problems Index I Score: Week 12 | -12.1 (-13.4 to -10.8) | -10.9 (-12.2 to -9.6) |
| Sleep Problems Index I Score: Week 16 | -13.3 (-14.5 to -12.0) | -11.0 (-12.2 to -9.8) |
| Sleep Problems Index I Score: Week 26 | -12.9 (-14.2 to -11.7) | -12.1 (-13.3 to -10.9) |
| Sleep Problems Index II Score: Week 12 | -14.4 (-15.7 to -13.1) | -12.2 (-13.5 to -10.9) |
| Sleep Problems Index II Score: Week 16 | -15.7 (-17.0 to -14.4) | -12.8 (-14.0 to -11.5) |
| Sleep Problems Index II Score: Week 26 | -15.4 (-16.7 to -14.1) | -14.0 (-15.2 to -12.7) |
The skin pain NRS was a participant reported outcome where participants were asked to rate the "worst skin pain" in the past 24 hours on a 11-point scale from 0=no skin pain to 10=worst skin pain imaginable. Higher scores indicated worse pain.
| Units on a scale | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | -3.7 (-3.9 to -3.4) | -2.6 (-2.8 to -2.3) |
| Week 12 | -4.5 (-4.7 to -4.2) | -4.0 (-4.3 to -3.8) |
| Week 16 | -4.4 (-4.7 to -4.2) | -4.2 (-4.4 to -4.0) |
| Week 20 | -4.8 (-5.0 to -4.5) | -4.5 (-4.7 to -4.2) |
| Week 26 | -4.5 (-4.8 to -4.3) | -4.3 (-4.6 to -4.1) |
Medicated topical background therapy-free days was defined as number of days where a participant maintained a response of EASI-90 or greater without the use of medicated topical background therapy.
| Days | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Medicated Topical Background Therapy-free Days | 51.4 (46.0 to 56.8) | 33.3 (27.9 to 38.7) |
DLQI was a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
| Percentage of participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | 81.3 (77.2 to 85.4) | 67.5 (62.6 to 72.4) |
| Week 12 | 85.4 (81.7 to 89.2) | 81.4 (77.4 to 85.5) |
| Week 16 | 82.7 (78.7 to 86.8) | 84.2 (80.4 to 88.1) |
| Week 20 | 81.8 (77.7 to 85.9) | 83.7 (79.8 to 87.6) |
| Week 26 | 76.6 (72.1 to 81.2) | 80.8 (76.7 to 84.9) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a treatment-emergent adverse event (TEAE) if the event started on or after the first dosing day until 28 days post last dose of study drug. AEs included both serious and non-serious AEs.
| Participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | 268 | 239 |
An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; a congenital anomaly/birth defect and other important medical events.
| Participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| SAEs | 6 | 6 |
| AEs Leading to Study Discontinuation | 12 | 9 |
The pre-defined criteria for laboratory parameters included: hemoglobin (\<9 grams per deciliter or decreases to \>=2 below baseline); platelets (\<75\*10\^3 cells per millimeter cube \[mm\^3\]); lymphocytes (\<0.5\*10\^3 cells per mm\^3); neutrophils (\<1\*10\^3 cells per mm\^3); aspartate aminotransferase and alanine aminotransferase (\>3\* upper limit of normal).
| Participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Laboratory Abnormalities Meeting Pre-Defined Criteria | 38 | 10 |
Vital signs including temperature, systolic and diastolic blood pressure, and pulse rate were measured in a seated position after 5 minutes rest. Clinically significant change from baseline in vital signs were determined by the investigator.
| Participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 |
A single 12-lead ECG was performed after the participant has rested for at least 10 minutes quietly in the supine position. Clinically significant change from baseline in ECG data was determined by the investigator.
| Participants | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Data | 0 | 0 |
Collected over From start of study intervention up to 28 days after last dose of study intervention (Up to Week 30). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abrocitinib 200 mg QD | 2/362 (0.6%) | 6/362 (1.7%) | 203/362 (56.1%) |
| Dupilumab 300 mg Q2W | 0/365 (0%) | 6/365 (1.6%) | 144/365 (39.5%) |
| Event | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| Cardio-respiratory arrestCardiac disorders | 1/362 | 0/365 |
| Cholecystitis acuteHepatobiliary disorders | 1/362 | 0/365 |
| COVID-19Infections and infestations | 1/362 | 0/365 |
| COVID-19 pneumoniaInfections and infestations | 1/362 | 0/365 |
| PneumoniaInfections and infestations | 1/362 | 0/365 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/362 | 0/365 |
| Haemorrhage intracranialNervous system disorders | 1/362 | 0/365 |
| Alanine aminotransferase increasedInvestigations | 0/362 | 1/365 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/362 | 1/365 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/362 | 1/365 |
| Event | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W |
|---|---|---|
| NauseaGastrointestinal disorders | 70/362 | 8/365 |
| HeadacheNervous system disorders | 47/362 | 24/365 |
| AcneSkin and subcutaneous tissue disorders | 46/362 | 10/365 |
| ConjunctivitisInfections and infestations | 8/362 | 35/365 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 17/362 | 13/365 |
| SARS-CoV-2 test positiveInvestigations | 15/362 | 13/365 |
| Oral herpesInfections and infestations | 9/362 | 15/365 |
| COVID-19Infections and infestations | 14/362 | 12/365 |
| NasopharyngitisInfections and infestations | 14/362 | 12/365 |
| Blood creatine phosphokinase increasedInvestigations | 14/362 | 13/365 |
Safety Analysis Set comprised of all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.
| Age, Continuous(Years) | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Mean | 36.6 ± 14.6 | 35.5 ± 13.3 | 36.0 ± 14.0 |
| Sex: Female, Male(Participants) | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Female | 169 | 161 | 330 |
| Male | 193 | 204 | 397 |
| Ethnicity (NIH/OMB)(Participants) | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 30 | 27 | 57 |
| Not Hispanic or Latino | 331 | 337 | 668 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Abrocitinib 200 mg QD | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 62 | 83 | 145 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 25 | 26 | 51 |
| White | 269 | 248 | 517 |
| More than one race | 0 | 3 | 3 |
| Unknown or Not Reported | 4 | 5 | 9 |
Showing the first 100 of 151 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2020 to primary completion in Jul 2021, 13 months.
Results were first posted in Jul 2022, 11 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib